FED LIQUIDITYReserve balances, repo dynamics and front-end funding volatility back at the centre of the macro debate•
US EQUITIESMega-cap index concentration stays extreme as leadership narrows to a handful of AI-linked names•
PRECIOUS METALSGold holds near record highs as central-bank buying and fiscal deficits underpin hard-asset demand•
CHINA POLICYBeijing stimulus and balance-sheet repair remain the swing factor for global trade and EM risk•
FX & RATESDollar cyclicality and rate-cut pricing drive the G10 carry and cross-asset positioning debate•
CREDITPrivate-credit spreads and liability-management activity keep restructuring desks fully occupied•
FED LIQUIDITYReserve balances, repo dynamics and front-end funding volatility back at the centre of the macro debate•
US EQUITIESMega-cap index concentration stays extreme as leadership narrows to a handful of AI-linked names•
PRECIOUS METALSGold holds near record highs as central-bank buying and fiscal deficits underpin hard-asset demand•
CHINA POLICYBeijing stimulus and balance-sheet repair remain the swing factor for global trade and EM risk•
FX & RATESDollar cyclicality and rate-cut pricing drive the G10 carry and cross-asset positioning debate•
CREDITPrivate-credit spreads and liability-management activity keep restructuring desks fully occupied•
GB • United KingdomAllocators, Wealth & Personal FinanceAnalysisfree

The Evidence-Based Investor

Evidence-Based Investing

Independent journalism on evidence-based investing and the fund industry.

TypeAnalysis
Asset ClassMulti-Asset
Nicheevidence-based investing
Birth Date2016
PriceFree
HeadquartersLondon, UK
Tierindependent

What it covers

The Evidence-Based Investor is an analysis publication focused on evidence-based investing. Its coverage spans Multi-Asset, and it is classified under allocator wealth with a uk orientation, based in London, UK.

Independent journalism on evidence-based investing and the fund industry.

#FinTwit#Analysis#Markets

Pricing and access

The Evidence-Based Investor is completely free to read. There is no paywall, which makes it one of the cheaper ways to follow evidence-based investing on a standing basis.

Track record

First published in 2016, which makes it roughly 10 years into its run. Vintage matters in research: surviving one full cycle is a different claim from surviving a bull market.

It carries a Research Authority Score of 76/100, ranked 237 of 444 publications in the index, and is classified as a independent publication.

Who it is for

The Evidence-Based Investor suits readers who want a thesis they can hold for quarters rather than a level to trade today. With a free access model and a focus on evidence-based investing, it fits readers who already know the sector and want depth rather than an introduction.

If your constraint is time rather than money, the question to ask is whether the publication tells you something the free feed does not: order flow, a primary-source ledger, a model, or a mechanism nobody else has priced.

How it is scored

Every publication in this index is scored 0 to 100 on the same five pillars: primary-source rigour (35%), differentiated niche edge (25%), track record and vintage (15%), institutional adoption (15%), and transparency and independence (10%). The Evidence-Based Investor scores 76.

Paid placement on this site affects visual prominence only. It never changes a publication's description, classification or score.

Frequently asked

How much does The Evidence-Based Investor cost?
The Evidence-Based Investor is free to read.
What does The Evidence-Based Investor cover?
The Evidence-Based Investor covers evidence-based investing, across Multi-Asset. It is published as a analysis publication from London, UK.
How is The Evidence-Based Investor ranked on newsletters.markets?
It scores 76/100, ranked 237 of 444 publications in the index. Scoring weights primary-source rigour, niche depth, track record, institutional adoption and transparency. Paid placement never changes the score.
What are the best alternatives to The Evidence-Based Investor?
The top alternatives to The Evidence-Based Investor include competing publications and research desks covering evidence-based investing in the allocator wealth sector. View the alternatives tab for side-by-side pricing and scores.
Who is The Evidence-Based Investor best for?
The Evidence-Based Investor is best suited for institutional investors, analysts, and active traders seeking analysis coverage in evidence-based investing.

Related Research Desks & Publications